Linda Rogers (Icahn School of Medicine at Mount Sinai, New York, NY, US) discusses the background and findings of her presentation entitled: A Real World, Single Center Experience of Treatment of Severe Eosinophilic Asthma with IL-5 Antagonists; Mepolizumab and Reslizumab (abstract available here: www.abstractsonline.com/pp8/#!/4499/presentation/12056).
Questions
1. Why is the treatment of eosinophilic asthma so challenging? (0:12)
2. What is the rationale for using interleukin 5 (IL-5) antagonists in patients with severe eosinophilic asthma? (0:43)
3. Could you tell us about your recent study investigating mepolizumab and reslizumab? (1:33)
4. Why do you think some patients who failed to respond to mepolizumab subsequently responded to reslizumab? (2:38)
5. What further studies are needed to optimise the use of these agents? (3:14)
Speaker disclosure: Linda Rogers has nothing to disclose in relation to this video interview.
Filmed at the American Thoracic Society (ATS) International Conference 2018, San Diego, CA, US, May 2018.
